fbpx

Weekly Top News – Psoriasis – August 12, 2019

August 12, 2019

BMS-986165 / BMS
BMS-986165 clinical trial estimate: Data from P3 trials POETYK-PSO-1 (NCT03624127) and POETYK-PSO-2 (NCT03611751) for moderate-to-severe plaque psoriasis in late 2020 (William Blair) – Aug 12, 2019 – A subscription to Thomson ONE is required to gain full access to report 67531579; Page no: 22; REPORT TITLE: “Bristol-Myers Squibb Co.: BMY: CheckMate-459 failure and deal closing delay for Otezla divestiture a double hit to sentiment”; AUTHOR: Phipps, Matt, et al; DATE: 06/24/2019

 

Stelara (ustekinumab) / J&J
Safety of Ustekinumab in Inflammatory Bowel Diseases: Integrated Safety Analysis of Results From Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis (ACG 2019) – Aug 8, 2019 – Abstract #P0505; Pres time: Oct 27, 2019; 03:30 PM – 07:00 PM; Location: Exhibit Halls 3 and 4 (Street Level); “At induction baseline (2370 pts in pooled phase 3 IBD studies), median age was 38.0 years, 46.9% were receiving corticosteroids, 30.8% were receiving IMM, 53.0% had failed biologics, and 37.1% were naïve to biologics. In phase 3 IBD studies, through Wk8 of PBO-controlled induction, the frequency of key safety events was similar between UST and PBO (Table 1). In addition, through 1 year across phase 2/3 IBD studies (Table 2), numbers of pts per 100 PY with key safety events were similar between treatment groups.”

 

bimekizumab (UCB4940) / UCB
Bimekizumab launch estimate: For psoriatic arthritis in 2022 (Kepler Cheuvreux) – Aug 12, 2019 – A subscription to Thomson ONE is required to gain full access to report 67604813; Page no: 19; REPORT TITLE: “UCB SA – Q&A report | UCB | Buy | What can really get UCB shares moving?”; AUTHOR: Evans, David, et al; DATE: 07/21/2019

 

Efleira (netakimab) / Biocad
Efleira clinical trial estimate: Initiation of pivotal trial in Europe for psoriasis in Q4 2019(GlobalData) – Aug 9, 2019 – A subscription to Thomson ONE is required to gain full access to report 66555904; Page no: 22; REPORT TITLE: “Biocad”; AUTHOR: GlobalData; DATE: 07/22/2019

 

Tremfya (guselkumab) / J&J
Tremfya pricing: Wholesale acquisition cost of $10,859/Injection (J.P. Morgan) – Aug 9, 2019 – A subscription to Thomson ONE is required to gain full access to report 67760273; Page no: 21; REPORT TITLE: “European Pharmaceuticals: Weekly chartbook: trx for week ending July 26th “; AUTHOR: Vosser, Richard, et al; DATE: 08/05/2019

 

Tremfya (guselkumab) / J&J
MorphoSys AG reports second quarter 2019 financial results (Market Watch) – Aug 6, 2019 – “An increasing royalty stream from Tremfya further strengthens our cash position and we are confident that there will be other compounds that follow Tremfya’s market entry in the future….Revenues also included an estimate of royalties on net sales of Tremfya amounting to EUR 7.1 million (estimate only since royalties for Q2 2019 had not been reported by Janssen as of the balance date)….Further phase 3 trials of Tremfya conducted by Janssen in psoriatic arthritis and a potential submission of a BLA planned for later this year as communicated by Janssen.”

 

Otezla (apremilast) / Celgene
Otezla sales projection: $2.7B in 2022 (Cowen & Co) – Aug 6, 2019 – A subscription to Thomson ONE is required to gain full access to report 67713313; Page no: 2; REPORT TITLE: “Celgene Corp – Solid Q2 – bb2121 filing likely early ’20, not clear if KarMMa data at ASH”; AUTHOR: Werber, Yaron, et al; DATE: 07/30/2019

 

ANB019 / AnaptysBio
AnaptysBio announces second quarter 2019 financial results and provides pipeline updates(AnaptysBio Press Release) – Aug 8, 2019 – “The Company is conducting a randomized, placebo-controlled, multi-dose Phase 2 trial in 50 patients with palmoplantar pustulosis, or PPP, also known as the POPLAR trial, with top-line data anticipated in the first half of 2020….Research and development expenses were $27.4 million and $48.0 million for the three and six months ended June 30, 2019, compared to $10.6 million and $22.4 million for the three and six months ended June 30, 2018. The increase was due primarily to continued advancement of the Company’s…ANB019 clinical programs…”

No Comments

Post a Comment

Comment
Name
Email
Website